Hematologic Malignancies Highlights: ASCO 2022

CME

Key Studies in Hematologic Malignancies: Independent Conference Coverage of the 2022 ASCO Annual Meeting

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: September 13, 2022

Expiration: September 12, 2023

John M. Burke
John M. Burke, MD
Shaji K. Kumar
Shaji K. Kumar, MD
Eunice S. Wang
Eunice S. Wang, MD

Activity

Progress
1
Course Completed

In this module, John M. Burke, MD; Shaji Kumar, MD; and Eunice S. Wang, MD, discuss key findings in hematologic malignancies presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

First, Eunice S. Wang, MD, will explore top studies related to the care of patients with acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). John M. Burke, MD, will then review the most clinically relevant studies in chronic lymphocytic leukemia (CLL) and other lymphomas including updates in advanced classic Hodgkin lymphoma (cHL), mantle cell lymphoma (MCL), relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), and R/R follicular lymphoma (FL). Finally, Shaji Kumar, MD, will discuss key studies on the care of patients with multiple myeloma (MM).

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with hematologic malignancies do you provide care for in a typical month?

Based on currently available evidence, which of the following regimens, either approved or investigational, would you recommend for a 75-year-old patient with newly diagnosed TP53-mutated AML and a good Eastern Cooperative Oncology Group (ECOG) performance status (PS) whose goal is to optimize their response to treatment?

Which of the following results was reported from the 96-week updated analysis of results from the ASCEMBL trial that compared asciminib with bosutinib in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP)?

In consultation with a patient with newly diagnosed stage IV cHL who needs to decide what treatment course to pursue, which of the following would you tell them about the frontline option of brentuximab vedotin (BV) plus doxorubicin, vinblastine, and dacarbazine (AVD) compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) based on the most recent 6-year follow-up data from the randomized phase III ECHELON-1 trial?

The European Commission has recommended conditional marketing authorization for teclistamab based on the results of the phase I/II MajesTEC-1 trial. In which of the following patient populations is teclistamab approved for use?